Latest news
Bank of America Securities Reaffirms Their Buy Rating on Avalo Therapeutics (AVTX) - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 10:59:00 GMTAVTX Maintains Buy Rating by Guggenheim -- Price Target Lowered to $48 - GuruFocusGuruFocus · Fri, 07 Aug 2026 19:15:45 GMTAVTX Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocusGuruFocus · Fri, 07 Aug 2026 14:33:10 GMTState Street Corporation (NYSE: AVTX custodian) discloses 5.5% Avalo stake - Stock TitanStock Titan · Fri, 07 Aug 2026 12:44:31 GMTAVTX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing - GuruFocusGuruFocus · Fri, 07 Aug 2026 08:03:26 GMTPrice-Driven Insight from (AVTX) for Rule-Based Strategy - Stock Traders DailyStock Traders Daily · Thu, 06 Aug 2026 23:20:02 GMTAvalo Therapeutics Releases Q2 2026 Financial Results - AlphaStreetAlphaStreet · Thu, 06 Aug 2026 18:46:31 GMTAvalo Therapeutics, Inc. Stock 12‑Month Price Target Raised to $45.33, Implies 141% Upside - TradingViewTradingView · Thu, 06 Aug 2026 17:20:07 GMT